海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy - Functional MRI in Prostate Cancer
- Prostata cancer MedDRA version: 9.1 Level: LLT Classification code 10007113 Term: Cancer of prostate
- Germany
- 2009-05-28
Authorised
- Safety and pharmacokinetics of ODM-204 in patients with metastatic castration -resistant prostate cancer: an open-label, non - randomised, uncontrolled, multicentre, dose escalation, first-in- man study with additional expansion phase with a dose selected in the escalation phase
- Metastatic castration resistant prostate cancer (mCRPC) MedDRA version: 18.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: LLT Classification code 10036916 Term: Prostate cancer stage D System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Finland, Latvia, United Kingdom
- 2014-10-29
Authorised
- Weekly cabazitaxel chemotherapy in elderly patients with advanced prostate cancer resistant to previous docetaxel treatment
- Castration resistant metastatic prostate cancer progressing after docetaxel based treatment MedDRA version: 17.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-09-16
Authorised
- Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer.
- Metastatic castration sensitive prostate cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2015-07-20
Authorised
- Zoledronic acid in patients with metastatic prostate cancer treated with abiraterone acetate: impact on bone mineral density
- Metastatic castration-resistant prostate cancer br>MedDRA version: 18.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- France
- 2015-06-17
Authorised
- An exploratory study to assess the efficacy using imaging of oral enzalutamide in patients with therapy-resistant prostate cancer who have not been treated with androgen deprivation.
- Patients with Metastatic Prostate Cancer who have never been treated with Androgen Deprivation Therapy MedDRA version: 18.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Austria, Belgium, Germany, Netherlands, Spain, Switzerland
- 2015-04-13
Authorised
- An exploratory study to assess the efficacy using imaging of oral Enzalutamide in patients with therapy-resistant prostate cancer who have not been treated with anti-androgens.
- Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients) MedDRA version: 18.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Austria, Belgium, Germany, Netherlands, Spain, Switzerland
- 2015-04-13
Authorised
- Is monitoring of plasmalevels of abiraterone a possible predictor for the response to Abiraterone treatment, in patients with metastatic prostate cancer?
- Metastatic Castration Resistant Prostate Cancer (mCRPC) MedDRA version: 19.1 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2015-01-15
Authorised
- Abirateriona acetate in combination with docetaxel after disease progression to abiraterona acetate in metastatic castration resistant prostate cancer.
- Metastatic castration resistant prostate cáncer MedDRA version: 16.1 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Spain
- 2013-11-12
Authorised
- An early study of onapristone safety and anti-cancer effect in patients with advanced prostate cancer that is not responding to other hormone treatments
- Advanced Castration-resistant Prostate Cancer br>MedDRA version: 19.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: PT Classification code 10036920 Term: Prostate cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: PT Classification code 10036911 Term: Prostate cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: LLT Classification code 10036910 Term: Prostate cancer NOS System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2013-11-07
